TRVI

Trevi Therapeutics, Inc. (TRVI) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. This report covers the quarterly period ended June 30, 2024. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no outstanding debt following the full repayment of its Silicon Valley Bank term loan in May 2023.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2024, increased by $9.3 million (58%) compared to the same period in 2023. This was driven primarily by a $7.4 million increase in clinical development expenses for the Phase 2b CORAL (IPF), Phase 2a RIVER (RCC), and Phase 1b TIDAL studies.
• Higher Net Loss: The net loss for the six months ended June 30, 2024, increased by $9.7 million compared to the prior year period, reflecting the accelerated clinical trial spending.
• Interest Income Decline: Interest income decreased by $0.5 million year-over-year due to lower average cash and marketable securities balances.
• Equity Financing: The company raised approximately $5.0 million in gross proceeds through its at-the-market (ATM) sales agreement during the first half of 2024.

Guidance, Outlook, and Risks

Clinical Outlook:

• IPF Program: The Phase 2b CORAL trial is ongoing with topline data expected in the first half of 2025. The Phase 1b TIDAL respiratory physiology study has initiated screening.
• RCC Program: The Phase 2a RIVER trial is approximately 80% enrolled, with topline data expected in Q4 2024.
• Abuse Potential: The Human Abuse Potential (HAP) study is approximately 95% enrolled, with topline data expected in Q4 2024.
• Prurigo Nodularis: The company does not intend to complete development for this indication independently and may seek a strategic collaboration.

Liquidity and Capital Resources:

• Management believes existing cash, cash equivalents, and marketable securities ($69.5 million) will fund operations into 2026.
• The company expects to incur substantial additional expenditures and will need to raise further capital to complete development and commercialization.

Key Risks:

• Single Product Dependence: The company is entirely dependent on the success of Haduvio.
• Regulatory Uncertainty: Risks include potential classification as a controlled substance, requirements for a Risk Evaluation and Mitigation Strategy (REMS), and the outcome of the HAP study.
• Supply Chain: Reliance on a single supplier (Mallinckrodt) for the active pharmaceutical ingredient, which recently emerged from bankruptcy.
• Profitability: The company has never been profitable and expects to incur significant losses for the foreseeable future.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "into 2026" funding estimate given the increased burn rate ($23.3M loss in H1 2024).
• Clinical Enrollment: Monitor the completion of the Phase 2a RIVER and HAP studies scheduled for Q4 2024.
• Supply Chain Stability: Assess the impact of Mallinckrodt's bankruptcy reorganization on the supply of nalbuphine hydrochloride.
• Regulatory Pathway: Track the FDA's response to the HAP study results regarding potential controlled substance scheduling.
• Dilution Risk: Review the significant number of outstanding warrants (approx. 38.3 million shares) and pre-funded warrants that could impact share price upon exercise.